These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 16384979

  • 1. Clearance of intravitreal moxifloxacin.
    Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER.
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):317-9. PubMed ID: 16384979
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal clearance of moxifloxacin.
    Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER.
    Trans Am Ophthalmol Soc; 2005 Jan; 103():76-81; discussion 81-3. PubMed ID: 17057790
    [Abstract] [Full Text] [Related]

  • 3. Clearance of intravitreal voriconazole.
    Shen YC, Wang MY, Wang CY, Tsai TC, Tsai HY, Lee YF, Wei LC.
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2238-41. PubMed ID: 17460285
    [Abstract] [Full Text] [Related]

  • 4. The effect of cataract surgery on ocular levels of topical moxifloxacin.
    Mather R, Stewart JM, Prabriputaloong T, Wong J, McLeod SD.
    Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780
    [Abstract] [Full Text] [Related]

  • 5. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
    Hariprasad SM, Shah GK, Chi J, Prince RA.
    J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
    [Abstract] [Full Text] [Related]

  • 6. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalakshmi R, Ramasamy K.
    Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
    [Abstract] [Full Text] [Related]

  • 7. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
    Hariprasad SM, Mieler WE, Shah GK, Blinder KJ, Apte RS, Holekamp NM, Thomas MA, Chi J, Prince RA.
    Trans Am Ophthalmol Soc; 2004 Nov; 102():149-55; discussion 155-7. PubMed ID: 15747753
    [Abstract] [Full Text] [Related]

  • 8. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
    Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP.
    Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
    Stewart WC, Crean CS, Zink RC, Brubaker K, Haque RM, Hwang DG.
    Am J Ophthalmol; 2010 Nov; 150(5):744-751.e2. PubMed ID: 20813346
    [Abstract] [Full Text] [Related]

  • 10. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
    Yağci R, Oflu Y, Dinçel A, Kaya E, Yağci S, Bayar B, Duman S, Bozkurt A.
    Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
    [Abstract] [Full Text] [Related]

  • 11. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
    Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA.
    Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810
    [Abstract] [Full Text] [Related]

  • 12. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, Gao H, Prince RA.
    Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
    [Abstract] [Full Text] [Related]

  • 13. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
    Asena L, Akova YA, Goktaş MT, Bozkurt A, Yaşar U, Karabay G, Demiralay E.
    Curr Eye Res; 2013 Apr; 38(4):472-9. PubMed ID: 23373761
    [Abstract] [Full Text] [Related]

  • 14. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.
    Ermis SS, Cetinkaya Z, Kiyici H, Inan UU, Ozturk F.
    Curr Eye Res; 2007 Apr; 32(4):337-44. PubMed ID: 17453955
    [Abstract] [Full Text] [Related]

  • 15. Vitreous and aqueous penetration of orally and topically administered moxifloxacin.
    Fukuda M, Shibata N, Osada H, Yamashiro Y, Sasaki H.
    Ophthalmic Res; 2011 Apr; 46(3):113-7. PubMed ID: 21325873
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR, Gajjar D, Raj SM, Vasavada V, Vasavada V.
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [Abstract] [Full Text] [Related]

  • 17. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing.
    Levine JM, Noecker RJ, Lane LC, Herrygers L, Nix D, Snyder RW.
    J Cataract Refract Surg; 2004 Oct; 30(10):2177-82. PubMed ID: 15474833
    [Abstract] [Full Text] [Related]

  • 18. Clearance of intravitreal daptomycin in uveitis-induced rabbit model.
    Ozcimen M, Sakarya Y, Ozcimen S, Sakarya R, Goktas S, Iyisoy S, Alpfidan I, Erdogan E.
    Curr Eye Res; 2015 May; 40(6):598-603. PubMed ID: 25110947
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models.
    Gao H, Pennesi ME, Qiao X, Iyer MN, Wu SM, Holz ER, Mieler WF.
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1606-11. PubMed ID: 16565399
    [Abstract] [Full Text] [Related]

  • 20. [Clearance of liposome-incorporated ciprofloxacin after intravitreal injection in rabbit eyes].
    Wiechens B, Krausse R, Grammer JB, Neumann D, Pleyer U, Duncker GI.
    Klin Monbl Augenheilkd; 1998 Nov; 213(5):284-92. PubMed ID: 9888133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.